Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial IntelligenceBusiness Wire • 01/07/26
This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131%Investors Business Daily • 12/26/25
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering PeriodBusiness Wire • 12/12/25
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions TranscriptSeeking Alpha • 12/11/25
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)Business Wire • 12/08/25
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular LymphomaBusiness Wire • 12/07/25
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)Business Wire • 12/06/25
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/04/25
How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next ChapterInvestors Business Daily • 12/04/25
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured NotesGlobeNewsWire • 12/03/25
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated PersonsGlobeNewsWire • 12/01/25
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in MiamiGlobeNewsWire • 11/24/25
Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/22/25
Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan FacilityGlobeNewsWire • 11/18/25
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness Wire • 11/18/25
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured NotesGlobeNewsWire • 11/10/25